If Ranveer Singh-starrer ‘Dhurandhar: The Revenge’ movie performs well at the Box Office, it could strengthen PVR-INOX’s revenue, market share, and profitability, brokerage firm Prabhudas Lilladher Capital (PL Capital) has said.
The brokerage firm cited Sacnilk data to mention that the film has collected around Rs 405 crore (gross) from paid previews, while advance bookings for March 19 (Day 1) have crossed Rs 290 crore. The figures reflect that Aditya Dhar’s ‘Dhurandhar: The Revenge’ could reach the top position in terms of all-time highest advance bookings.
The first part of the movie, ‘Dhurandhar’, which released in 2025, had collected around Rs 8,400 crore in India. PL Capital expects the movie sequel to storm the Box Office and shatter the part 1 record.
The brokerage said, ‘Dhurandhar: The Revenge’ would benefit from the popularity of the first part and no film is releasing in the upcoming weeks. Notably, Yash starrer ‘Toxic’, was scheduled to be released on 19 March. However, the firm has postponed its release.
The movie which has stars such as Sanjay Dutt, Arjun Rampal, is releasing in multi-languages..
In Q4 2025-26, the total box office collection (NBOC) is around Rs 15,000 crore. However, ‘Dhurandhar: The Revenge’ could completely change these figures.
The film is expected to save the last quarter of the current financial year for PVR-INOX. Notably, except ‘Border-2’, films like ‘O’Romeo’, ‘Mardani-3’, and ‘The Kerala Story-2’ have failed to attract audiences to the cinemas. Thus trade analysts are saying that the success of the Ranveer Singh-helmed ‘Dhurandhar: The Revenge’ could prove to be a major game changer for the multiplex sector.
If the film earns Rs 10 billion (base case) and 75% of that comes within the first two weeks, then the total quarterly collection could reach last year’s level. This could significantly benefit PVR-INOX.
Initiating a Buy rating on PVR-INOX stock, PL Capital projected the shares to reach Rs 1,274 apiece. The stock settled at Rs 1,024.80 on March 18, 2026.
(Disclaimer: This article is only meant to provide information. News9 does not recommend buying or selling shares or subscriptions of any IPO.)